Funding to Drive Nanoscale Technology for Healthcare - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Funding to Drive Nanoscale Technology for Healthcare


ePT--the Electronic Newsletter of Pharmaceutical Technology

The UK’s Technology Strategy Board has partnered with the Engineering and Physical Sciences Research Council (EPSRC) to invest as mush as £9 million ($14.2 million) in grant funding with the aim of bringing proof-of-concept ideas to pilot technology demonstration for healthcare.

The Technology Strategy Board is a UK government body sponsored by the Department for Business, Innovation, and Skills (BIS), and charged with bringing together the business community, researchers, and the public sector to meet market needs and build the future economy. The specific goal of this project is to ensure that the healthcare sector adopts emerging novel nanoscale technology-enabled solutions by providing support to a commercialization route through innovative businesses.

The focus is on highly innovative, collaborative research in nanoscale technology-enabled solutions that deliver therapeutics and diagnostics. About £3 million ($4.75 million) is available for businesses (through the Technology Strategy Board), and £6 million ($9.49 million) is available for participation by academia (through the EPSRC). Collaborations to be considered must be business-led, but draw at least one partner from large or small businesses, academia, research, and technology organizations, or not-for-profit organizations. Projects can receive between £500,000 ($791,200) and £2 million ($3.16 million).

The Technology Strategy Board will accept applications from Nov. 1, 2011 until Dec. 13, 2011. Further information can be found here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here